Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population.

Hartung DM, Middleton L, McFarland BH, Haxby DG, McDonagh MS, McConnell KJ.

Psychiatr Serv. 2013 Dec 1;64(12):1236-42. doi: 10.1176/appi.ps.005482012.

PMID:
23999754
2.

Off-label use of antipsychotic medications in Medicaid.

Leslie DL, Rosenheck R.

Am J Manag Care. 2012 Mar 1;18(3):e109-17.

3.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

4.

The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Matone M, Localio R, Huang YS, dosReis S, Feudtner C, Rubin D.

Health Serv Res. 2012 Oct;47(5):1836-60. doi: 10.1111/j.1475-6773.2012.01461.x. Epub 2012 Sep 4.

5.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
6.

Off-label use of second-generation antipsychotic agents among elderly nursing home residents.

Kamble P, Sherer J, Chen H, Aparasu R.

Psychiatr Serv. 2010 Feb;61(2):130-6. doi: 10.1176/ps.2010.61.2.130.

PMID:
20123817
7.

Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.

Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla DN.

Am J Manag Care. 2014 Feb 1;20(2):e52-60.

8.

Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.

Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.

J Med Econ. 2011;14(6):777-86. doi: 10.3111/13696998.2011.625066. Epub 2011 Sep 29.

PMID:
21954966
9.

Off-label use of antipsychotic medications in the department of Veterans Affairs health care system.

Leslie DL, Mohamed S, Rosenheck RA.

Psychiatr Serv. 2009 Sep;60(9):1175-81. doi: 10.1176/ps.2009.60.9.1175.

PMID:
19723731
10.

Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.

Morrato EH, Campagna EJ, Brewer SE, Dickinson LM, Thomas DS, Miller BF, Dearing J, Druss BG, Lindrooth RC.

JAMA Psychiatry. 2016 Jul 1;73(7):721-30. doi: 10.1001/jamapsychiatry.2016.0538.

PMID:
27167755
11.

Prescribing of antipsychotics in UK primary care: a cohort study.

Marston L, Nazareth I, Petersen I, Walters K, Osborn DP.

BMJ Open. 2014 Dec 18;4(12):e006135. doi: 10.1136/bmjopen-2014-006135.

12.

Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders.

Wu CS, Wang SC, Yeh IJ, Liu SK.

J Clin Psychiatry. 2016 May;77(5):e573-9. doi: 10.4088/JCP.15m09898.

PMID:
27249081
13.

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims.

Stephenson JJ, Tunceli O, Gu T, Eisenberg D, Panish J, Crivera C, Dirani R.

Int J Clin Pract. 2012 Jun;66(6):565-73. doi: 10.1111/j.1742-1241.2012.02918.x. Epub 2012 May 11. Erratum in: Int J Clin Pract. 2012 Jul;66(7):723. Tuncelli, O [corrected to Tunceli, O].

14.

Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.

Zito JM, Burcu M, Ibe A, Safer DJ, Magder LS.

Psychiatr Serv. 2013 Mar 1;64(3):223-9. doi: 10.1176/appi.ps.201200081.

PMID:
23242390
16.

Validation of a claims-based antipsychotic polypharmacy measure.

Leckman-Westin E, Kealey E, Gupta N, Chen Q, Gerhard T, Crystal S, Olfson M, Finnerty M.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):628-35. doi: 10.1002/pds.3609. Epub 2014 Mar 24.

17.

Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia.

Lawson W, Johnston S, Karson C, Offord S, Docherty J, Eramo A, Kamat S, Blanchette CM, Carson W, Nasrallah HA.

Ann Clin Psychiatry. 2015 Nov;27(4):242-52.

PMID:
26554365
18.

Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.

Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM.

J Clin Psychiatry. 2011 Aug;72(8):1079-85. doi: 10.4088/JCP.09m05348yel. Epub 2010 Oct 19.

PMID:
21034690
19.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
20.

Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.

Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O.

Eur Child Adolesc Psychiatry. 2017 Apr;26(4):413-420. doi: 10.1007/s00787-016-0905-7. Epub 2016 Sep 13.

PMID:
27623818

Supplemental Content

Support Center